Emerging therapeutic targets for retinoblastoma

References

• Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. BMJ Publishing Group Ltd; 2009. p. 1129–1131.
   Google Scholar
• Parkin DM, Stiller CA, Draper GJ, et al. The international incidence of childhood cancer. Int J Cancer. 1988;42(4):511–520.
   PubMed Web of Science ®Google Scholar
• Kaliki S, Patel A, Iram S, et al. Retinoblastoma in India: clinical presentation and outcome in 1,457 patients (2,074 eyes). Retina. 2019;39(2):379–391.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Meshram M, Kumar A, et al. Survival and outcome of retinoblastoma treated by neo‐adjuvant chemotherapy in India. Cancer Rep. 2019;2(3):e1137.
   Google Scholar
• Munier FL, Beck-Popovic M, Chantada GL, et al. Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace.“Alive, with good vision and no comorbidity.” Prog Retin Eye Res. 2019;73:100764.
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73(3):692–698.
   PubMed Web of Science ®Google Scholar
• Tomar AS, Finger PT, Gallie B, et al. Global retinoblastoma treatment outcomes: association with national income level. Ophthalmology. 2021;128(5):740–753.
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Nat Acad Sci. 1971;68(4):820–823.
   PubMed Web of Science ®Google Scholar
• Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012;379(9824):1436–1446.
   PubMed Web of Science ®Google Scholar
• Nork TM, Schwartz TL, Doshi HM, et al. Retinoblastoma: cell of origin. Arch Ophtalmol. 1995;113(6):791–802.
   PubMedGoogle Scholar
• Kyritsis A, Tsokos M, Triche T, et al. Retinoblastoma—origin from a primitive neuroectodermal cell? Nature. 1984;307(5950):471–473.
   PubMed Web of Science ®Google Scholar
• Xu XL, Singh HP, Wang L, et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature. 2014;514(7522):385–388.
   PubMed Web of Science ®Google Scholar
• Singh HP, Wang S, Stachelek K, et al. Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors. Proc Nat Acad Sci. 2018;115(40):E9391–E9400.
   PubMed Web of Science ®Google Scholar
• Liu J, Ottaviani D, Sefta M, et al. A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nat Commun. 2021;12(1):1–20.
   PubMed Web of Science ®Google Scholar
• Seigel GM, Campbell LM, Narayan M, et al. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005;11(12):729–737.
   PubMedGoogle Scholar
• Seigel GM, Hackam AS, Ganguly A, et al. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 2007;13:823.
   PubMed Web of Science ®Google Scholar
• Balla MM, Vemuganti GK, Kannabiran C, et al. Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. Invest Ophthalmol Vis Sci. 2009;50(4):1506–1514.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–848.
   PubMed Web of Science ®Google Scholar
• Laurie NA, Donovan SL, Shih C-S, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444(7115):61–66.
   PubMed Web of Science ®Google Scholar
• Brennan RC, Federico S, Bradley C, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res. 2011;71(12):4205–4213.
   PubMed Web of Science ®Google Scholar
• Lau L, Nugent J, Zhao X, et al. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene. 2008;27(7):997–1003.
   PubMed Web of Science ®Google Scholar
• Yao X, Shen H, Peng Q, et al. TP53/miR-129/MDM2/4/TP53 feedback loop modulates cell proliferation and apoptosis in retinoblastoma. Cell Cycle. 2021;20(5–6):603–615.
   PubMed Web of Science ®Google Scholar
• Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8(5):361–375.
   PubMed Web of Science ®Google Scholar
• Kim D-R, Rah SH, Sohn JH, et al. Calcium mobilization by activation of M3/M5 muscarinic receptors in the human retinoblastoma. J Pharmacol Sci. 2007;105(2):184–192.
   PubMed Web of Science ®Google Scholar
• Mergler S, Cheng Y, Skosyrski S, et al. Altered calcium regulation by thermosensitive transient receptor potential channels in etoposide-resistant WERI-Rb1 retinoblastoma cells. Exp Eye Res. 2012;94(1):157–173.
   PubMed Web of Science ®Google Scholar
• Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system—implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta-Mol Cell Res. 2014;1843(1):150–162.
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans. 2007;35(1):12–17.
   PubMedGoogle Scholar
• Thibaudeau TA, Smith DM, Ma Q. A practical review of proteasome pharmacology. Pharmacol Rev. 2019;71(2):170–197.
   PubMed Web of Science ®Google Scholar
• Poulaki V, Mitsiades CS, Kotoula V, et al. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007;48(10):4706–4719.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liang X, Zhou J, et al. Exosomes in the pathogenesis and treatment of ocular diseases. Exp Eye Res. 2021;209:108626.
   PubMed Web of Science ®Google Scholar
• Ruivo CF, Adem B, Silva M, et al. The biology of cancer exosomes: insights and new perspectives Biology of cancer exosomes. Cancer Res. 2017;77(23):6480–6488.
   PubMed Web of Science ®Google Scholar
• Manukonda R, Attem J, Yenuganti VR, et al. Exosomes in the visual system: new avenues in ocular diseases. Tumor Biol. 2022;44(1):129–152.
   PubMedGoogle Scholar
• Chen S, Chen X, Qiu J, et al. Exosomes derived from retinoblastoma cells enhance tumour deterioration by infiltrating the microenvironment. Oncol Rep. 2021;45(1):278–290.
   PubMed Web of Science ®Google Scholar
• Tsering T, Laskaris A, Abdouh M, et al. Uveal melanoma-derived extracellular vesicles display transforming potential and carry protein cargo involved in metastatic niche preparation. Cancers (Basel). 2020;12(10):2923.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Yang Y, Mei Q. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression. Mol Vis. 2015;21:1307.
   PubMed Web of Science ®Google Scholar
• Martin J, Bryar P, Mets M, et al. Differentially expressed miRNAs in retinoblastoma. Gene. 2013;512(2):294–299.
   PubMed Web of Science ®Google Scholar
• Xu X, Jia R, Zhou Y, et al. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011;38(5):1385–1393.
   PubMed Web of Science ®Google Scholar
• Galardi A, Colletti M, Lavarello C, et al. Proteomic profiling of retinoblastoma-derived exosomes reveals potential biomarkers of vitreous seeding. Cancers (Basel). 2020;12(6):1555.
   PubMed Web of Science ®Google Scholar
• Manukonda R, Yenuganti VR, Nagar N, et al. Comprehensive analysis of serum small extracellular vesicles-derived coding and non-coding RNAs from retinoblastoma patients for identifying regulatory interactions. Cancers (Basel). 2022;14(17):4179.
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134.
   PubMed Web of Science ®Google Scholar
• Kim J-K, Jeon H-Y, Kim H. The molecular mechanisms underlying the therapeutic resistance of cancer stem cells. Arch Pharm Res. 2015;38(3):389–401.
   PubMed Web of Science ®Google Scholar
• Narayana RV, Jana P, Tomar N, et al. Carboplatin-and etoposide-loaded lactoferrin protein nanoparticles for targeting cancer stem cells in retinoblastoma in vitro. Invest Ophthalmol Vis Sci. 2021;62(14):13.
   PubMed Web of Science ®Google Scholar
• Nair RM, Balla M, Khan I, et al. In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line. BMC Cancer. 2017;17(1):1–12.
   PubMedGoogle Scholar
• Hu H, Deng F, Liu Y, et al. Characterization and retinal neuron differentiation of WERI-Rb1 cancer stem cells. Mol Vis. 2012;18:2388.
   PubMed Web of Science ®Google Scholar
• Balaji S, Santhi R, Kim U, et al. Cancer stem cells with overexpression of neuronal markers enhance chemoresistance and invasion in retinoblastoma. Curr Cancer Drug Targets. 2020;20(9):710–719.
   PubMed Web of Science ®Google Scholar
• Balicki D, Beaulieu R. Cancer stem cell side populations. In: Bapat SA, editor. cancer stem cells: identification and Targets. John Wiley & Sons; 2008. p. 73.
   Google Scholar
• Winter U, Aschero R, Fuentes F, et al. Tridimensional retinoblastoma cultures as vitreous seeds models for live-cell imaging of chemotherapy penetration. Int J Mol Sci. 2019;20(5):1077.
   PubMed Web of Science ®Google Scholar
• Pascual-Pasto G, Olaciregui NG, Vila-Ubach M, et al. Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Lett. 2016;380(1):10–19.
   PubMed Web of Science ®Google Scholar
• Youssef NS, Said AM. Said AMJIjoc, pathology e. Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. Inter J Cli Experi Pathol. 2014;7(9):5725.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou S, Brodowska K, Kayama M, et al. Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. PloS one. 2013;8(1):e52852.
   PubMed Web of Science ®Google Scholar
• Santiago JG, Burgos-Tirado N, Lafontaine DD, et al. Adhesion G protein-coupled receptor, ELTD1, is a potential therapeutic target for retinoblastoma migration and invasion. BMC Cancer. 2021;21(1):1–13.
   PubMed Web of Science ®Google Scholar
• Pina Y, Boutrid H, Murray TG, et al. Impact of tumor-associated macrophages in LHBETATAG Mice on retinal tumor progression: relation to macrophage subtype. Invest Ophthalmol Vis Sci. 2010;51(5):2671–2677.
   PubMed Web of Science ®Google Scholar
• Gallud A, Warther D, Maynadier M, et al. Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles. RSC advances. 2015;5(92):75167–75172.
   Web of Science ®Google Scholar
• Basavarajappa HD, TWJFmc C. KIF14 as an oncogene in retinoblastoma: a target for novel therapeutics? Future Med Chem. 2012;4(17):2149–2152.
   PubMed Web of Science ®Google Scholar
• O’Hare M, Shadmand M, Sulaiman RS, et al. Kif14 overexpression accelerates murine retinoblastoma development. Inter JCancer. 2016;139(8):1752–1758.
   PubMed Web of Science ®Google Scholar
• Jockovich M-E, Suarez F, Alegret A, et al. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. Investig Ophthalmol Vis Sci. 2007;48(12):5371–5376.
   PubMed Web of Science ®Google Scholar
• Dalgard CL, Van Quill KR, Jmjccr O. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res: an Official J of the American Association for Cancer Res. 2008;14(10):3113–3123.
   PubMed Web of Science ®Google Scholar
• Elison JR, Cobrinik D, Claros N, et al. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol (Chicago, Ill.: 1960). 2006;124(9):1269–1275.
   PubMedGoogle Scholar
• Li J, Di C, Jing J, et al. OTX2 is a therapeutic target for retinoblastoma and may function as a common factor between C-MYC, CRX, and phosphorylated RB pathways. Inter J Oncol. 2015;47(5):1703–1710.
   PubMed Web of Science ®Google Scholar
• Chai Y, Xiao J, Du Y, et al. A novel treatment approach for retinoblastoma by targeting epithelial growth factor receptor expression with a shRNA lentiviral system. Iran J Basic Med Sci. 2017;20(7):739.
   PubMed Web of Science ®Google Scholar
• Sousa DC, Zoroquiain P, Orellana ME, et al. HER2 overexpression in retinoblastoma: a potential therapeutic target. Ocul Oncol Pathol. 2017;3(3):210–215.
   PubMed Web of Science ®Google Scholar
• Asnaghi L, White DT, Key N, et al. ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma. Oncogene. 2019;38(12):2056–2075.
   PubMed Web of Science ®Google Scholar
• Piña Y, Decatur C, Murray T, et al. Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBetaTag retinal tumors. Cli Ophthalmol (Auckland, N.Z.). 2011;5:337.
   PubMedGoogle Scholar
• Pina Y, Houston SK, Murray TG, et al. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci. 2010;51(12):6149–6156.
   PubMed Web of Science ®Google Scholar
• Ii RP, Chan -C-C, Ni M, et al. Human retinoblastoma cells express αB-crystallin in vivo and in vitro. Curr Eye Res. 1993;12(3):239–245.
   PubMed Web of Science ®Google Scholar
• Kase S, Parikh JG, NAJAoo R. Expression of α-crystallin in retinoblastoma. Arch Ophthalmol (Chicago, Ill.: 1960). 2009;127(2):187–192.
   PubMedGoogle Scholar
• Martin A, Jones A, Bryar PJ, et al. MicroRNAs-449a and-449b exhibit tumor suppressive effects in retinoblastoma. Biochem Biophys Res Commun. 2013;440(4):599–603.
   PubMed Web of Science ®Google Scholar
• Pascual-Pasto G, Bazan-Peregrino M, Olaciregui NG, et al. Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med. 2019;11(476). DOI: 10.1126/scitranslmed.aat9321
   PubMed Web of Science ®Google Scholar
• Nalini V, Deepa PR, Raguraman R, et al. Targeting HMGA2 in retinoblastoma cells in vitro using the aptamer strategy. Ocular Oncology and Pathology. 2016;2(4):262–269.
   PubMedGoogle Scholar
• Apte RS, Harbour JW. Inhibiting angiogenesis in retinoblastoma. Ophthalmic Res. 2007;39(4):188.
   PubMed Web of Science ®Google Scholar
• Di Fiore R, Drago-Ferrante R, D’Anneo A, et al. In human retinoblastoma Y79 cells okadaic acid–parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player. Cancer Biol Ther. 2013;14(10):922–931.
   PubMed Web of Science ®Google Scholar
• Liu K, Liu Y, Zhao G. Targeting survivin suppresses proliferation and invasion of retinoblastoma cells in vitro and in vivo. Int J Clin Exp Pathol. 2017;10(9):9352.
   PubMed Web of Science ®Google Scholar
• Allaman-Pillet N, Oberson A, Munier F, et al. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells. Ophthalmic Genet. 2013;34(1–2):1–13.
   PubMed Web of Science ®Google Scholar
• Mao Y, Sun Y, Wu Z, et al. Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy. Cell Death Dis. 2021;12(12):1–11.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang L, Liu D, et al. Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis. Cell Death Discov. 2022;8(1):1–11.
   PubMed Web of Science ®Google Scholar
• Kalmodia S, Parameswaran S, Ganapathy K, et al. Characterization and molecular mechanism of peptide-conjugated gold nanoparticle inhibiting p53-HDM2 interaction in retinoblastoma. Molecular Therapy - Nucleic Acids. 2017;9:349–364.
   Google Scholar
• Aubry A, Pearson JD, Huang K, et al. Functional genomics identifies new synergistic therapies for retinoblastoma. Oncogene. 2020;39(31):5338–5357.
   PubMed Web of Science ®Google Scholar
• Bird A. Perceptions of epigenetics. Nature. 2007;447(7143):396.
   PubMed Web of Science ®Google Scholar
• Wainwright EN, Scaffidi P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer. 2017;3(5):372–386.
   PubMed Web of Science ®Google Scholar
• Singh U, Malik MA, Goswami S, et al. Epigenetic regulation of human retinoblastoma. Tumor Biol. 2016;37(11):14427–14441.
   PubMedGoogle Scholar
• Greger V, Passarge E, Höpping W, et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet. 1989;83(2):155–158.
   PubMed Web of Science ®Google Scholar
• Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481(7381):329–334.
   PubMed Web of Science ®Google Scholar
• Kim JK, Kan G, Mao Y, et al. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress‐mediated apoptosis. Mol Oncol. 2020;14(2):329–346.
   PubMed Web of Science ®Google Scholar
• Zocchi L, Wu SC, Benavente CA. Heavenly HELLS? A potential new therapeutic target for retinoblastoma. Oncoscience. 2020;7(3–4):23.
   PubMedGoogle Scholar
• Nagare R P, Sneha S, Krishna Priya S, et al. Cancer stem cells–are surface markers alone sufficient? Curr Stem Cell Res Ther. 2017;12(1):37–44.
   PubMed Web of Science ®Google Scholar
• Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009;18(1):17–26.
   PubMed Web of Science ®Google Scholar
• Mitra M, Kandalam M, Harilal A, et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis. 2012;18:290–308.
   Web of Science ®Google Scholar
• Salem ML, El-Badawy AS, Li Z. Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy. Cytotechnology. 2015;67(5):749–759.
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16(12):3153–3162.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang H, Wang X, et al. The molecular mechanism and regulatory pathways of cancer stem cells. Cancer Trans Med. 2016;2(5):1–6.
   PubMedGoogle Scholar
• Asnaghi L, Tripathy A, Yang Q, et al. Targeting Notch signaling as a novel therapy for retinoblastoma. Oncotarget. 2016;7(43):70028.
   PubMedGoogle Scholar
• Song Z, Du Y, Tao Y. Blockade of sonic hedgehog signaling decreases viability and induces apoptosis in retinoblastoma cells: the key role of the PI3K/Akt pathway. Oncol Lett. 2017;14(4):4099–4105.
   PubMed Web of Science ®Google Scholar
• Wu S, Han M, Zhang C. Overexpression of microRNA‐186 inhibits angiogenesis in retinoblastoma via the Hedgehog signaling pathway by targeting ATAD2. J Cell Physiol. 2019;234(10):19059–19072.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Corominas-Faja B, Cuyàs E, et al. Metabostemness: metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience. 2014;1(12):803.
   PubMedGoogle Scholar
• Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab. 2012;16(1):9–17.
   PubMed Web of Science ®Google Scholar
• Vandhana S, Coral K, Jayanthi U, et al. Biochemical changes accompanying apoptotic cell death in retinoblastoma cancer cells treated with lipogenic enzyme inhibitors. Biochim Biophys Acta (BBA)-Mol Cell Biol Lipids. 2013;1831(9):1458–1466.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Ravi Kumar RK, Nicolay B, et al. Metabolite systems profiling identifies exploitable weaknesses in retinoblastoma. FEBS Lett. 2019;593(1):23–41.
   PubMed Web of Science ®Google Scholar